CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 127 enrolled
Drug / intervention
Trospium Chloride, Extended Release (XR) +1 moredrug
Likely dose
Trospium Chloride, Extended Release (XR) 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00932022
NCT00932022Phase 4Completed
CompareCT.gov

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

Allergan·interventional·Posted Jul 2, 2009·Updated Jan 21, 2013

In Brief

A Phase 4 clinical trial evaluating Trospium Chloride, Extended Release (XR) and placebo for Obesity and 2 related conditions. Completed, enrolled 127 participants across 1 site.

Detailed Summary

This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overactive Bladder, Incontinence
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2, 2009
Enrollment StartJul 1, 2009
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17 years ago

Interventions

Trospium Chloride, Extended Release (XR)drug

Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.

placeboother

Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.